RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of “Buy” by Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the […]
More Stories
Consolidated Lithium Metals (CVE:CLM) Hits New 12-Month Low – Here’s What Happened
Consolidated Lithium Metals Inc. (CVE:CLM – Get Free Report) reached a new 52-week low during trading on Monday . The...
GSTechnologies (LON:GST) Hits New 12-Month High – Still a Buy?
GSTechnologies Ltd. (LON:GST – Get Free Report)’s share price reached a new 52-week high on Monday . The company traded...
AGC (OTCMKTS:ASGLY) Hits New 12-Month Low – Here’s Why
AGC Inc. (OTCMKTS:ASGLY – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock...
CMC Metals (CVE:CMB) Sets New 52-Week Low – Should You Sell?
CMC Metals Ltd. (CVE:CMB – Get Free Report) hit a new 52-week low on Wednesday . The company traded as...
Vistry Group (LON:VTY) Stock Price Down 16.1% – Should You Sell?
Vistry Group PLC (LON:VTY – Get Free Report)’s share price dropped 16.1% during mid-day trading on Wednesday . The stock...
Versarien (LON:VRS) Trading Up 3.4% – Here’s Why
Versarien plc (LON:VRS – Get Free Report) shares traded up 3.4% on Monday . The stock traded as high as...